Xencor begins phase 1 trial of XmAb23104 in advanced solid tumors

This article was originally published here

Through the early-stage trial called DUET-3, Xencor will assess the safety and tolerability of XmAb23104 in an estimated 144 patients with selected advanced solid tumors. The participants will

The post Xencor begins phase 1 trial of XmAb23104 in advanced solid tumors appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply